- Home
- AIRS vs SERA Comparison
AIRS vs SERA Comparison
Compare AIRS & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | SERA |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.3M | 134.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIRS | SERA |
|---|---|---|
| Price | $2.88 | $3.05 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.75 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 67.0K |
| Earning Date | 03-13-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $157,554,000.00 | $95,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | $2.55 | $715.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $1.53 | $1.37 |
| 52 Week High | $12.00 | $6.92 |
Technical Indicators
Market Signals| Indicator | AIRS | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 39.94 |
| Support Level | $2.15 | $3.30 |
| Resistance Level | $3.15 | $3.69 |
| Average True Range (ATR) | 0.35 | 0.24 |
| MACD | 0.16 | -0.05 |
| Stochastic Oscillator | 63.89 | 2.13 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.